«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 07

Page:

1362-1366

Research Field:

Publishing date:

Info

Title:

Advances in the internal medicine treatment of small cell lung cancer

Author(s):

Aliya Aosiman¹; WANG Xiaogang¹; LIU Junyuan²; Patiguli Aerxiding²

1.The Third Clinical Medical College of Xinjiang Medical University,Tumor Hospital Affiliated to Xinjiang Medical University,Xinjiang Urumqi 830011,China;2.Department of Thoracic Oncology,the Third Clinical Medical College of Xinjiang Medical University,Tumor Hospital Affiliated to Xinjiang Medical University,Xinjiang Urumqi 830011,China.

Keywords:

small cell lung cancer(SCLC); chemotherapy; drug resistant; anti-vascular therapy; immunotherapy

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2023.07.037

Abstract:

Small cell lung cancer(SCLC) has a very high proliferation rate,a strong tendency to metastasise early and a poor prognosis.More than two-thirds of patients are initially diagnosed with extensive stage(ES-SCLC).Treatment of small cell lung cancer has progressed slowly and platinum-containing chemotherapy has been the standard of care,which,although recently highly effective,is prone to drug resistance.The rise of immunotherapy and anti-vascular agents in recent years has led to breakthroughs in the field of SCLC,establishing a new standard of care for SCLC.This article reviews advances in chemotherapy,anti-vascular therapy and immunotherapy for SCLC.

References:

£Û1£ÝSUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries£ÛJ£Ý.CA Cancer J Clin,2021,71(3):209-249.
£Û2£ÝRUDIN CM,BRAMBILLA E,FAIVRE-FINN C,et al.Small-cell lung cancer£ÛJ£Ý.Nat Rev Dis Primers,2021,7(1):1-20.
£Û3£ÝHERZOG BH,DEVARAKONDA S,GOVINDAN R.Overcoming chemotherapy resistance in SCLC£ÛJ£Ý.J Thorac Oncol,2021£¬16£¨12£©£º2002-2015.
£Û4£ÝREMON J,ALDEA M,BESSE B,et al.Small cell lung cancer:a slightly less orphan disease after immunotherapy£ÛJ£Ý.Ann Oncol,2021,32(6):698-709.
£Û5£ÝROSSI A,DI MAIO M,CHIODINI P,et al.Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer:the COCIS meta-analysis of individual patient data£ÛJ£Ý.J Clin Oncol,2012,30(14):1692-1698.
£Û6£ÝZUGAZAGOITIA JON,PAZ-ARES LUIS.Extensive-stage small-cell lung cancer:First-Line and second-line treatment options£ÛJ£Ý.J Clin Oncol,2022,40:671-680.
£Û7£ÝOWONIKOKO TK,BEHERA M,CHEN Z,et al.A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer£ÛJ£Ý.J Thorac Oncol,2012,7(5):866-872.
£Û8£ÝBAIZE N,MONNET I,GREILLIER L,et al.Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer:An open-label,multicentre,randomised,phase 3 trial£ÛJ£Ý.Lancet Oncol,2020,21(9):1224-1233.
£Û9£ÝGOTO K,OHE Y,SHIBATA T,et al.Combined chemotherapy with cisplatin,etoposide,and irinotecan versus topotecan alone as second-line treatment for patientswith sensitive relapsed small-cell lung cancer(JCOG0605):A multicentre,open-label,randomised phase 3 trial£ÛJ£Ý.Lancet Oncol,2016,17(8)£º1147-1157.
£Û10£ÝGEORGE J,LIM JS,JANG SJ,et al.Comprehensive genomic profiles of small cell lung cancer£ÛJ£Ý.Nature,2015,524(7563):47-53.
£Û11£ÝLEAL JF,MART¦PNEZ-D¦PEZ M,GARC¦PA-HERN¦BNDEZ V,et al.PM01183,a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity£ÛJ£Ý.Br J Pharmacol,2010,161(5):1099-1110.
£Û12£ÝSANTAMAR¦PA NU¦rEZ G,ROBLES CM,GIRAUDON C,et al.Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells£ÛJ£Ý.Mol Cancer Ther,2016,15(10):2399-2412.
£Û13£ÝXIE W,FORVEILLE S,IRIBARREN K,et al.Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity£ÛJ£Ý.Oncoimmunology,2019,8(11):1656502.
£Û14£ÝTRIGO J,SUBBIAH V,BESSE B,et al.Lurbinectedin as second-line treatment for patients with small-cell lung cancer:A single-arm,open-label,phase 2 basket trial£ÛJ£Ý.Lancet Oncol,2020,21(5):645-654.
£Û15£ÝHORITA N,YAMAMOTO M,SATO T,et al.Topotecan for relapsed small-cell lung cancer:Systematic review and Meta-analysis of 1347 patients£ÛJ£Ý.Sci Rep,2015,5:15437.
£Û16£ÝÕÅˬ,³ÌÓ±.Сϸ°û·Î°©ÖÎÁÆнøÕ¹£ÛJ£Ý.ÖйúÖ×ÁöÁÙ´²,2021,48(10):501-505. ZHANG S,CHENG Y.Advances in the treatment of small-cell lung cancer£ÛJ£Ý.Chin J Clin Oncol,2021,48(10):501-505.
£Û17£ÝONODA S,MASUDA N,SETO T,et al.Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer:Thoracic oncology research group study 0301£ÛJ£Ý.J Clin Oncol,2006,24(34):5448-5453.
£Û18£ÝINOUE A,SUGAWARA S,YAMAZAKI K,et al.Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer:North Japan lung cancer study group trial 0402£ÛJ£Ý.J Clin Oncol,2008,26(33):5401.
£Û19£ÝVON PAWEL J,JOTTE R,SPIGEL DR,et al.Randomized phase III trial of Amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer£ÛJ£Ý.J Clin Oncol,2014,32(35):4012.
£Û20£ÝSCHULZE AB,EVERS G,KERKHOFF A,et al.Future options of molecular-targeted therapy in small cell lung cancer£ÛJ£Ý.Cancers,2019,11(5):690.
£Û21£ÝHAN B,LI K,ZHAO Y,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:a multicentre,randomised phase II trial(ALTER0302)£ÛJ£Ý.Br J Cancer,2018,118(5):654-661.
£Û22£ÝFAN Y,ZHAO J,WANG Q,et al.Camrelizumab plus apatinib in extensive-stage small cell lung cancer(PASSION):A multicenter,twostage,phase 2 trial£ÛJ£Ý.J Thorac Oncol,2021,16(2):299-309.
£Û23£ÝLIU SV,RECK M,MANSFIELD AS,et al.Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated withatezolizumab,carboplatin,and etoposide(IMpower133)£ÛJ£Ý.J Clin Oncol,2021,39:619-630.
£Û24£ÝHORN L,MANSFIELD AS,SZCZE ESNA A,et al.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer£ÛJ£Ý.N Engl J Med,2018,379(23):2220-2229.
£Û25£ÝGOLDMAN JW,DVORKIN M,CHEN Y,et al.Durvalumab,with or without tremelimumab,plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):updated results from a randomised,controlled,open-label,phase 3 trial£ÛJ£Ý.Lancet Oncol,2021,22(1):51-65.
£Û26£ÝRUDIN CM,AWAD MM,NAVARRO A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phase III KEYNOTE-604 study£ÛJ£Ý.J Clin Oncol,2020,38(21):2369-2379.
£Û27£ÝYU H,CHEN P,CAI XY,et al.Effcacy and safety of PD L1 inhibitors versus PD 1 inhibitors in first line treatment with chemotherapy for extensive stage small cell lung cancer£ÛJ£Ý.Cancer Immunol Immunother,2022,71:637-644.
£Û28£ÝPETERS S,PUJOL JL,DAFNI U,et al.Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy-results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial£ÛJ£Ý.Ann Oncol,2022,33(1):67-79.
£Û29£ÝREADY NE,OTT PA,HELLMANN MD,et al.Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer:results from the CheckMate 032 randomized cohort£ÛJ£Ý.J Thorac Oncol,2020,15:426-435.
£Û30£ÝCHUNG HC,PIHA-PAUL SA,LOPEZ-MARTIN J,et al.Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC:results from the KEYNOTE-028 and KEYNOTE-158 studies£ÛJ£Ý.J Thorac Oncol,2020,15(4):618-627.
£Û31£ÝMARABELLE A,FAKIH M,LOPEZ J,et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab:prospective biomarker analysis of the multicohort,open-label,phase 2 KEYNOTE-158 study£ÛJ£Ý.Lancet Oncol,2020,21(10):1353-1365.
£Û32£ÝOTT PA,BANG YJ,PIHA-PAUL SA,et al.T-cell-inflamed gene-expression profile,programmed death ligand 1 expression,and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers:KEYNOTE-028£ÛJ£Ý.J Clin Oncol,2019,37(4):318-327.
£Û33£ÝSUN S,LIU Y,EISFELD AK,et al.Identification of germline mismatch repair gene mutations in lung cancer patients with paired tumor-normal next generation sequencing:A retrospective study£ÛJ£Ý.Front Oncol,2019,9:550.
£Û34£ÝRICCIUTI B,CHENG M,RECONDO G,et al.DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from PD-1 axis inhibition in NSCLC£ÛJ£Ý.J Thorac Oncol,2019,14(10):S439-S440.
£Û35£ÝPARK S,LEE H,LEE B,et al.DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC£ÛJ£Ý.J Thorac Oncol,2019,14(9):1640-1650.
£Û36£ÝLU Y,JIANG J,REN C.The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer:A meta-analysis£ÛJ£Ý.PLoS One,2020,15(4):e0230979.
£Û37£ÝGAY CM,STEWART CA,PARK EM,et al.Patterns of tranion factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities£ÛJ£Ý.Cancer Cell,2021,39(3):346-360.
£Û38£ÝDORA D,RIVARD C,YU H,et al.Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution£ÛJ£Ý.Mol Oncol,2020,14(9):1947-1965.
£Û39£ÝлÃÎÇà,´¢ÏãÁá,Öܾê,µÈ. Сϸ°û·Î°©ÃâÒßÖÎÁÆÏà¹ØÉúÎï±êÖ¾ÎïÑо¿½øÕ¹£ÛJ£Ý.Öйú°©Ö¢ÔÓÖ¾,2021,31(7):635-639. XIE MQ,CHU XL,ZHOU J,et al.The advances in immunotherapy biomarkers of small cell lung cancer£ÛJ£Ý.China Oncol,2021,31(7):635-639.

Memo

Memo:

н®Î¬Îá¶û×ÔÖÎÇø×ÔÈ»¿Æѧ»ù½ð(±àºÅ:2022D01C294)

Common functions

Last Update: 2023-02-28